Literature DB >> 2729932

Penetration of pefloxacin into bronchial secretions.

G Bonmarchand1, J J Grès, G Lerebours, P Massari, J J Mayoux, A Montay, J Leroy.   

Abstract

Twelve patients, intubated for acute exacerbation of chronic obstructive pulmonary disease, received six intravenous doses of 400 mg of pefloxacin at 12-h intervals. Samples of blood and bronchial secretions were taken simultaneously, before the injection and at 0.5, 3, 6, 9, and 12 h after the end of the sixth infusion. There was a large variation in pefloxacin levels in both serum and bronchial secretions. The mean concentrations of pefloxacin in bronchial secretions ranged from 6.51 to 11.1 micrograms/ml and were higher than the corresponding concentrations in serum at all times. Of 61 bronchial specimens, 48 (79%) contained more than 8 micrograms of the antibiotic per ml.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2729932      PMCID: PMC171499          DOI: 10.1128/AAC.33.3.391

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  [Initial antibiotherapy in severe bacterial bronchopneumopathies. Randomized study of a new quinolone: pefloxacin].

Authors:  F Fourrier; C Chopin; P Lestavel; C Savage
Journal:  Presse Med       Date:  1986-06-28       Impact factor: 1.228

2.  Endobronchial Polymyxin B: experimental observations in chronic bronchitis.

Authors:  J Ramirez; E F O'Neill
Journal:  Chest       Date:  1970-10       Impact factor: 9.410

3.  [Clofibrate pharmacokinetics in chronic renal failure (author's transl)].

Authors:  H Millart; S Lavaud; J P Brunois; D Lamiable; H Choisy; J Chanard
Journal:  Therapie       Date:  1980 Nov-Dec       Impact factor: 2.070

4.  Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients.

Authors:  R A Salata; M M Lederman; D M Shlaes; M R Jacobs; E Eckstein; D Tweardy; Z Toossi; R Chmielewski; J Marino; C H King
Journal:  Am Rev Respir Dis       Date:  1987-02

5.  Pefloxacin in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

6.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  [Pefloxacine: diffusion into bronchial mucus].

Authors:  C Morel; M Vergnaud; M Langeard; Y Benard
Journal:  Pathol Biol (Paris)       Date:  1984-06

8.  Penetration of aztreonam into human bronchial secretions.

Authors:  D L Bechard; S S Hawkins; R Dhruv; L T Friedhoff
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

9.  Comparative in vitro studies with 4-quinolone antimicrobials.

Authors:  D Felmingham; M D O'Hare; M J Robbins; R A Wall; A H Williams; A W Cremer; G L Ridgway; R N Grüneberg
Journal:  Drugs Exp Clin Res       Date:  1985

10.  The comparative in-vitro activity of pefloxacin.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  1 in total

Review 1.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.